Intec pharma ltd. (NTEC)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
OPERATING EXPENSES:
RESEARCH AND DEVELOPMENT EXPENSES

-

-

-

15,349

7,533

LESS - PARTICIPATION IN RESEARCH AND DEVELOPMENT EXPENSES

-

-

-

4,600

2,718

RESEARCH AND DEVELOPMENT EXPENSES, net

26,659

35,402

24,295

10,749

4,815

GENERAL AND ADMINISTRATIVE EXPENSES

8,287

7,926

5,144

-

-

IMPAIRMENT OF LONG-LIVED ASSETS

13,663

-

-

-

-

OTHER INCOME

1,500

-

-

-

-

OPERATING LOSS

-47,109

-43,328

-29,439

-

-

FINANCIAL INCOME (EXPENSES), net

148

-112

559

-

-

LOSS BEFORE INCOME TAX

-46,961

-43,440

-28,880

-

-

INCOME TAX

638

103

29

-

-

NET LOSS

-47,599

-43,543

-28,909

-

-

LOSS PER ORDINARY SHARE - BASIC AND DILUTED (in dollars per share)

-1.41

-1.40

-1.64

-

-

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER ORDINARY SHARE IN THOUSANDS

33

31

17

-

-

GENERAL AND ADMINISTRATIVE EXPENSES

-

-

-

3,097

2,788

OTHER GAINS (LOSSES), net

-

-

-

34

19

OPERATING LOSS

-

-

-

-13,812

-7,584

FINANCIAL INCOME

-

-

-

466

633

FINANCIAL EXPENSES

-

-

-

16

229

FINANCIAL INCOME (EXPENSES), net

-

-

-

450

404

LOSS BEFORE TAXES ON INCOME

-

-

-

-13,362

-7,180

NET LOSS

-

-

-

-13,362

-7,180

OTHER COMPREHENSIVE LOSS - CURRENCY TRANSLATION DIFFERENCES

-

-

-

-

-664

LOSS AND COMPREHENSIVE LOSS

-

-

-

-13,362

-7,844

BASIC AND DILUTED LOSS PER ORDINARY SHARE

-

-

-

-1.17

-0.92